Posterior pituitary tumors: review of histogenetic continuum, molecular drivers and targetable therapies

Abstract Background Posterior pituitary tumors (PPTs) are rare sellar neoplasms arising from pituicytes. Historically classified as distinct benign entities, including pituicytoma (or classical pituicytoma), spindle cell oncocytoma (SCO), granular cell tumor (GCT) of the sellar region, and ependymal pituicytoma, recent World Health Organization updates have unified them within a single pathological spectrum. Methods This review comprehensively synthesizes the evidence supporting the spectrum concept, integrating clinical, histopathological, genomic, epigenomic, and tumor immune microenvironmental findings of pituicytomas, SCOs and GCTs. As ependymal pituicytomas are extremely rare, we synthetize their findings separately at the end of the review. Results Clinically, PPTs may mimic non-functioning pituitary adenomas or present as suprasellar masses, and can cause neurological and endocrine deficits due to mass effect. Surgery remains the treatment of choice, with radiotherapy considered for selected patients. Recent molecular studies have provided important insights into their biology. Chromosomal copy number variations (CNV) distinguished PPTs into three major prognostic subtypes: CNV-negative pituicytomas and SCOs associated with more favorable outcomes than the CNV-positive subtypes, and a third group composed of GCTs that have favorable outcomes. Additionally, PPTs exhibit substantial driver diversity: pituicytomas and SCOs are enriched for pathogenic variants in the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathways associated with downstream phosphorylated extracellular signal-regulated kinase (pERK) activation, whereas GCTs are characterized by relative genomic stability. Moreover, SCOs display an immune-active microenvironment, contrasting with the highly immunosuppressive profile observed in pituicytomas. Conclusion These genomic and immune discoveries provide a rational for targeted therapy for refractory PPTs.

Authors

Publication Details

Journal
Pituitary
Published
2026-11-13
DOI
https://doi.org/10.1007/s11102-026-01786-3
Primary Topic
Pituitary Gland Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Posterior pituitary tumors: review of histogenetic continuum, molecular drivers and targetable therapies

Elisa Baranski Lamback, Mônica R. Gadelha, Anna Clara Castro Araújo
Pituitary
Pituitary Gland Disorders and Treatments
article

Posterior pituitary tumors: review of histogenetic continuum, molecular drivers and targetable therapies

Elisa Baranski Lamback, Mônica R. Gadelha, Anna Clara Castro Araújo
article en

Abstract

Abstract Background Posterior pituitary tumors (PPTs) are rare sellar neoplasms arising from pituicytes. Historically classified as distinct benign entities, including pituicytoma (or classical pituicytoma), spindle cell oncocytoma (SCO), granular cell tumor (GCT) of the sellar region, and ependymal pituicytoma, recent World Health Organization updates have unified them within a single pathological spectrum. Methods This review comprehensively synthesizes the evidence supporting the spectrum concept, integrating clinical, histopathological, genomic, epigenomic, and tumor immune microenvironmental findings of pituicytomas, SCOs and GCTs. As ependymal pituicytomas are extremely rare, we synthetize their findings separately at the end of the review. Results Clinically, PPTs may mimic non-functioning pituitary adenomas or present as suprasellar masses, and can cause neurological and endocrine deficits due to mass effect. Surgery remains the treatment of choice, with radiotherapy considered for selected patients. Recent molecular studies have provided important insights into their biology. Chromosomal copy number variations (CNV) distinguished PPTs into three major prognostic subtypes: CNV-negative pituicytomas and SCOs associated with more favorable outcomes than the CNV-positive subtypes, and a third group composed of GCTs that have favorable outcomes. Additionally, PPTs exhibit substantial driver diversity: pituicytomas and SCOs are enriched for pathogenic variants in the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathways associated with downstream phosphorylated extracellular signal-regulated kinase (pERK) activation, whereas GCTs are characterized by relative genomic stability. Moreover, SCOs display an immune-active microenvironment, contrasting with the highly immunosuppressive profile observed in pituicytomas. Conclusion These genomic and immune discoveries provide a rational for targeted therapy for refractory PPTs.

PituitaryVol. 29(6)
Pituitary Gland Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon